

## R E M A R K S

Reconsideration and reexamination of the subject application are respectfully requested in light of the foregoing amendments and following remarks.

**1. Status of the Claims**

Claims 1-28 are pending and subject to restriction. By entry of the present amendment, claims 1 and 12-27 are canceled, and claims 2-11 are amended to depend on elected claim 28.

The amendments are made without prejudice or disclaimer of the canceled subject matter. Applicants reserve the right to file a continuing or divisional application on any subject matter canceled by way of amendment.

Claim 28 is amended to replace "including" with "comprising," in accord with typical claim drafting language.

**2. Restriction Requirement**

In the restriction requirement mailed October 2, 2007, the Office requires restriction of the invention to one of the following groups:

**Group I**, claims 1-11 drawing to a composition having an action preventing or alleviating symptoms or diseases due to aging of blood vessels, including any one of arachidonic acid and a compound having arachidonic acid as a component fatty acid; or

**Group II**, claims 12-23, drawn to a food or beverage having an action preventing or alleviating symptoms or diseases due to aging of blood vessels, including any one of arachidonic acid and a compound having arachidonic acid as a component fatty acid; or

**Group III**, claim 24, drawn to a food or beverage comprises of a combination of arachidonic acid and at least one of eicosapentaenoic acid and docosahexaenoic acid wherein the ratio of the arachidonic acid and said at least one of lecosapentaenoic acid and docosahexaenoic acid is in the range of 0.25 to 8; or

**Group IV**, claims 25-26, drawing to a food or beverage including at least 0.001% (weight) of a triglyceride with a medium-chain fatty acid bonded to the 1,3-position and with arachidonic acid bonded to the 2-position; or

**Group V**, claim 27, drawn to a method of producing a food or beverage having an action preventing or alleviating symptoms or diseases due to aging of the blood vessels, including blending in at least one of a arachidonic acid and a compound having arachidonic acid as a component fatty acid alone or together with a food or beverage ingredient in which arachidonic acid is substantially not contained or is contained in a slight amount; or

**Group VI**, claim 28, drawn to a method for prevention or treatment of symptoms or diseases due to aging of the blood vessels, including administering a subject requiring that administration one of arachidonic acid and a compound having arachidonic acid as a component fatty acid.

**2. Election**


Applicants elect **Group VI without traverse**. Claims that read on the elected Group are claims 28 and amended claims 2-11.

**CONCLUSION**

Should additional fees be necessary in connection with the filing of this paper, or if a petition for extension of time is required for timely acceptance of same, the Commissioner is hereby authorized to charge Deposit Account No. 50-0573 for any such fees; and Applicants hereby petition for any needed extension of time.

Respectfully submitted,

Date: October 30, 2007

By:   
\_\_\_\_\_  
Brian K. Lathrop, Ph.D., Esq.  
Registration No. 43,740  
DRINKER BIDDLE & REATH LLP  
1500 K Street, NW Suite 1100  
Washington, D.C. 20005  
T: (202) 842-8862  
F: (202) 842-8465